These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 24012083)

  • 21. A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey.
    Yalcin O; Kaymak G; Erdogan A; Tanidir C; Karacetin G; Kilicoglu AG; Mutlu C; Adaletli H; Gunes H; Bahali K; Ayik B; Uneri OS
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):815-821. PubMed ID: 26771824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Childhood and adolescent-onset schizophrenia: new information and definitions].
    Amitai M; Sever Y; Weizman A; Zalsman G
    Harefuah; 2012 Sep; 151(9):550-3, 554. PubMed ID: 23367752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polypharmacy with second-generation antipsychotics: a review of evidence.
    Pandurangi AK; Dalkilic A
    J Psychiatr Pract; 2008 Nov; 14(6):345-67. PubMed ID: 19057237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses.
    Buckley PF
    J Clin Pharmacol; 1997 May; 37(5):363-78. PubMed ID: 9156369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder.
    Lerner V; Libov I; Kotler M; Strous RD
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):89-98. PubMed ID: 14687862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of Oculogyric Crisis and Long-Term Outcomes With Second-Generation Antipsychotics in a First-Episode Psychosis Program.
    Gardner DM; Abidi S; Ursuliak Z; Morrison J; Teehan MD; Tibbo PG
    J Clin Psychopharmacol; 2015 Dec; 35(6):715-8. PubMed ID: 26485339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clozapine use in a forensic population in a New South Wales prison hospital.
    Martin A; O'Driscoll C; Samuels A
    Aust N Z J Psychiatry; 2008 Feb; 42(2):141-6. PubMed ID: 18197509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
    Moncrieff J
    Acta Psychiatr Scand; 2006 Jul; 114(1):3-13. PubMed ID: 16774655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of treatment-resistant patients with schizophrenia.
    Marder SR
    J Clin Psychiatry; 1996; 57 Suppl 11():26-30. PubMed ID: 8941168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the potential effect of polypharmacy on the hematologic profiles of clozapine patients.
    Shuman MD; Trigoboff E; Demler TL; Opler LA
    J Psychiatr Pract; 2014 Jan; 20(1):50-8. PubMed ID: 24419309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital.
    Stone-Brown K; Naji M; Francioni A; Myers K; Samarendra H; Mushtaq-Chaudhry H; Heslop S; Sengupta S; Ross CC; Larkin F; Das M
    CNS Spectr; 2016 Feb; 21(1):60-9. PubMed ID: 26726766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
    Elie D; Poirier M; Chianetta J; Durand M; Grégoire C; Grignon S
    J Psychopharmacol; 2010 Jul; 24(7):1037-44. PubMed ID: 19164494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empirical evidence for psychopharmacologic treatment in early-onset psychosis and schizophrenia.
    Maloney AE; Yakutis LJ; Frazier JA
    Child Adolesc Psychiatr Clin N Am; 2012 Oct; 21(4):885-909. PubMed ID: 23040906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antipsychotic polypharmacy or monotherapy?
    Gardos G
    Neuropsychopharmacol Hung; 2005 Jun; 7(2):72-7. PubMed ID: 16167458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy, safety, and tolerability of antipsychotics in the elderly.
    Maixner SM; Mellow AM; Tandon R
    J Clin Psychiatry; 1999; 60 Suppl 8():29-41. PubMed ID: 10335669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
    Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; Jones PB
    Schizophr Bull; 2006 Oct; 32(4):715-23. PubMed ID: 16540702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.